11 Nov Psychedelics 101 & 102 for Clinicians
This 2-day training offered by psychologists Ingmar Gorman and Elizabeth Nielson is designed for clinicians and healthcare providers who want to learn more about current psychedelic research and clinical practice, including how to work with patients who have a history of psychedelic use or have expressed an interest in using psychedelics. Sign up for either or both days (recommended!).
Psychedelics 101: Your patients are curious and so are you: What is all this about psychedelics being used for treatment of addiction and trauma? This session gives an overview of psychedelic drugs, their history, and current research with MDMA and Psilocybin-assisted therapy. This program includes overview of recent and current clinical trials, outcomes, legal status, and what it all means for the future of addiction and trauma treatment.
State the historical justifications for psychedelic clinical research
Describe key theoretical approaches to psychedelic-assisted therapy
Discuss the state of psychedelic clinical research, rescheduling efforts, and how psychedelic-assisted psychotherapy works with clients.
Define and differentiate psychedelic integration psychotherapy from integration in peer and shamanic settings
Psychedelics 102: What are psychedelic harm reduction and integration and how can they occur in a clinical setting? This session focuses on translating research findings into clinical practice including working with patients who are considering using psychedelics, actually using psychedelics, or have used them. This program includes discussion of assessment and integration techniques, resources, and legal and ethical issues.
Identify key “red flags” that indicate someone should seek specialized psychiatric care after a psychedelic experience
Perform basic/initial assessment of clients who report psychedelic use
Identify contraindications and discuss high risk cases of individuals who are contemplating psychedelic use
Define and differentiate the role of the therapist in an individual’s psychotherapeutic process
CONTINUING EDUCATION INFORMATION
CE credits for psychologists are provided by the Spiritual Competency Resource Center (SCRC) which is co-sponsoring this program. The Spiritual Competency Resource Center is approved by the American Psychological Association to sponsor continuing education for psychologists. The Spiritual Competency Resource Center maintains responsibility for this program and its content. SCRC is approved by the California Board of Registered Nursing (BRN Provider CEP16887) for licensed nurses in California. The California Board of Behavioral Sciences accepts CE credits for LCSW, LPCC, LEP, and LMFT license renewal for programs offered by approved sponsors of CE by the American Psychological Association. For questions about receiving your Certificate of Attendance, contact Woodstock Mindfulness at CE@marverde.info. For questions about CE, visit www.spiritualcompetency.com or contact David Lukoff, PhD at CE@spiritualcompetency.com
Full program cost: $400 | Single day cost: $225
APA CE credits available for purchase: $50 for 2-days
Ingmar Gorman, Ph.D., is a psychologist who specializes in assisting populations who have had experiences with psychedelics and other psychoactive compounds. He is the Director of the Psychedelic Education and Continuing Care Program, where he leads groups, trainings, and works with individual clients. Dr. Gorman is also site co-principal Investigator and therapist on a Phase 3 clinical trial studying the potential psychotherapeutic utility of MDMA for post-traumatic stress disorder. He is a NIH funded fellow at New York University and a board member of Horizons Media, Inc., a not for-profit educational charity and organizer of the Horizons Conference: Perspectives on Psychedelics.
Dr. Elizabeth Nielson is a psychologist with a holistic, compassionate, and integrative approach to psychotherapy. She specializes in treating addictive and mood disorders with a blend of of mindfulness-based interventions, dialectical behavior therapy, psychodynamic therapy, community reinforcement and family training (CRAFT), and principles of psychedelic-assisted therapy. Dr. Nielson’s work is guided by the idea that each individual has within them the capacity for growth and change, and sets out to support the natural healing process by building awareness, autonomy, and self-compassion. Dr. Nielson is part of the Experimental Therapeutics Research Laboratory at NYU Langone School of Medicine where she is a therapist on the psilocybin-assisted treatment for alcohol dependence trial and on the MDMA-assisted psychotherapy for PTSD clinical trials.